April 23, 2018
1 min read

Relypsa Inc. announces research grants to improve care of patients with kidney, heart diseases

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Relypsa Inc., a Vifor Pharma Group company, recently awarded three research grants to supplement institutional funding for nephrology and/or cardiology fellows pursuing a career in hyperkalemia and associated disorders, according to a press release issued by Relypsa. The grants will support research that aims to improve the care of patients with kidney and heart diseases.

Institutions receiving the research grants, up to $50,000 each for a single academic year, include the University of Cincinnati, Emory University and the University of Chicago.

“Our research grants aim to improve patient care, encourage disease awareness and educate health care organization and professionals,” Alain Romero, PhD, PharmD, vice president of medical and scientific affairs of Relypsa, said in the press release. “We are excited for the recipients of the Relypsa Nephrology and Cardiology Research Grant Program and look forward to seeing the results of their research.”

Aims of the grants include defining the frequency of hyperkalemia in solid organ transplant recipients and correlating hyperkalemia episodes to clinical episodes with greater accuracy; exploring the influence of potassium and urea levels on fibrosis in animal models of renal dysfunction; and following patients prospectively at a single site who require treatment with either a renin angiotensin system blocker and/or a mineralocorticoid receptor antagonist to improve blood pressure and/or cardiac function.